| Fiscal period | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2015 | 2014 | 2013 | 2012 |
|---|
| Period End Date | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 6/30/2015 | 6/30/2014 | 6/30/2013 | 6/30/2012 |
|---|
| Sales | -- | -- | -- | 4,946.20 | 5,280.60 | 2,632.20 | 4,227.10 | 3,914.10 | 3,539.80 | 3,173.20 |
| Total Revenues | 5,063.30 | 4,837.40 | 4,731.70 | 4,946.20 | -- | 2,632.20 | 4,227.10 | 3,914.10 | 3,539.80 | 3,173.20 |
| Cost of sales | 3,248.10 | 3,064.10 | 2,900.20 | 2,966.70 | 3,228.80 | 1,553.30 | 2,582.90 | 2,462.00 | 2,259.80 | 2,077.70 |
| PPA product discontinuation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross Profit | 1,815.20 | 1,773.30 | 1,831.50 | 1,979.50 | 2,051.80 | 1,078.90 | 1,644.20 | 1,452.10 | 1,280.00 | 1,095.50 |
| Goodwill impairment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Research and development | 177.70 | 187.40 | 218.60 | 167.70 | 184.00 | 88.20 | 187.80 | 152.50 | 115.20 | 105.80 |
| Write-off of in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | 9.00 | -- |
| Selling and administration | -- | -- | -- | -- | -- | -- | -- | -- | -- | 148.30 |
| Selling | 579.10 | 567.00 | 595.70 | 598.40 | 665.00 | 325.90 | 319.00 | 208.60 | 186.10 | -- |
| Distribution | 100.40 | 96.10 | 94.20 | 87.00 | 88.30 | 47.90 | 67.70 | 55.30 | 47.50 | 39.10 |
| Administration | 496.00 | 503.00 | 435.90 | 461.10 | 452.20 | 306.80 | 385.30 | 411.30 | 240.20 | 224.40 |
| Restructuring | 3.50 | 26.30 | 21.00 | 61.00 | 31.00 | 26.90 | 5.10 | 47.00 | 2.90 | 8.80 |
| Impairment charges | (346.80) | (184.50) | (224.40) | (47.50) | (2,631.00) | (215.60) | (6.80) | (6.00) | -- | -- |
| Other operating income | 3.70 | (4.20) | (5.20) | 41.40 | 0.00 | 0.00 | -- | -- | -- | -- |
| Total Operating Expenses | 1,699.80 | 1,568.50 | 1,595.00 | 1,381.30 | 4,051.50 | 1,011.30 | 971.70 | 880.70 | 600.90 | 526.40 |
| Operating Income (Loss) | 115.40 | 204.80 | 236.50 | 598.20 | (1,999.70) | 67.60 | 672.50 | 571.40 | 679.10 | 569.10 |
| Interest, net | 131.20 | 121.70 | 128.00 | 168.10 | 216.60 | 89.90 | 146.00 | 103.50 | 65.80 | 60.70 |
| Write-off of in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Investment impairment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Unusual litigation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other income (loss) net | (17.20) | 66.00 | (6.10) | 10.10 | (22.70) | (25.20) | (334.20) | (25.10) | (5.60) | 3.50 |
| Gain (loss) on extinguishment of debt | (20.00) | (0.20) | (0.50) | (135.20) | (1.10) | (0.90) | (10.50) | (165.80) | -- | -- |
| Tysabri®royalty stream - change in fair value | (96.40) | 22.10 | 188.70 | (24.90) | (2,608.20) | 57.30 | 78.50 | 26.60 | -- | -- |
| Income (loss) before income taxes | (149.40) | 171.00 | 290.60 | 280.10 | (4,848.30) | 8.90 | 260.30 | 303.60 | 607.70 | 512.00 |
| Pre-tax income: U.S | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Pre-tax income: Foreign | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Current- Foreign | 47.40 | 16.10 | 75.10 | 46.10 | 26.70 | 53.00 | 67.40 | 49.10 | (10.90) | 9.10 |
| Current: Federal | -- | -- | -- | (8.10) | 0.30 | 58.90 | 77.20 | 42.80 | 125.00 | 74.90 |
| Current: State | 17.60 | 51.00 | 66.40 | 100.40 | 93.70 | 3.00 | 6.80 | 9.30 | 10.70 | 7.50 |
| Deferred | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Deferred: Federal | (0.10) | 0.00 | (13.90) | 13.10 | (549.40) | (34.40) | (19.90) | 8.40 | 16.60 | 32.60 |
| Deferred: State | (52.30) | (30.20) | 7.30 | 7.80 | (12.70) | (3.30) | (0.80) | (5.80) | -- | 1.40 |
| Deferred: Foreign | (2.10) | (9.80) | 2.00 | 1.20 | (394.10) | (89.30) | (15.40) | (15.10) | 24.30 | (6.60) |
| Income tax expense (benefit) | 13.20 | 24.90 | 159.60 | 160.50 | (835.50) | (33.60) | 124.20 | 70.80 | 165.80 | 119.00 |
| Current:Ireland | 2.70 | (2.20) | 22.70 | -- | 0.30 | 1.60 | -- | -- | -- | -- |
| Deferred (credit):Ireland | (0.10) | -- | (13.90) | -- | (549.40) | (23.10) | -- | -- | -- | -- |
| Income (loss) from Continuing Operations | -- | -- | -- | -- | -- | -- | -- | -- | -- | 393.00 |
| Income (loss) from Discontinued Operations, net of tax | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.60 |
| Net income attributable to common shareholders | (162.60) | 146.10 | 131.00 | 119.60 | (4,012.80) | 42.50 | 136.10 | 232.80 | 441.90 | 401.60 |
| Earnings Per Share (Basic) - Cont Ops | -- | -- | -- | -- | -- | -- | -- | -- | -- | 4.22 |
| EPS (Basic) : Disc Ops | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.09 |
| Net Earnings Per Share (Basic) | (1.19) | 1.07 | 0.95 | 0.84 | (28.01) | 0.29 | 0.97 | 2.02 | 4.71 | 4.31 |
| Earnings Per Share (Diluted) - Cont Ops | -- | -- | -- | -- | -- | -- | -- | -- | -- | 4.18 |
| Earnings Per Share (Diluted) - Disc Ops | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.09 |
| Net Earnings Per Share (Diluted) | (1.19) | 1.07 | 0.95 | 0.84 | (28.01) | 0.29 | 0.97 | 2.01 | 4.68 | 4.27 |
| Weighted Average Shares Outstanding (Basic) | 136.10 | 136.00 | 137.80 | 142.30 | 143.30 | 145.60 | 139.30 | 115.10 | 93.90 | 93.20 |
| Weighted Average Shares Outstanding (Diluted) | 136.10 | 136.50 | 138.30 | 142.60 | 143.30 | 146.10 | 139.80 | 115.60 | 94.50 | 94.10 |